UNSPSC 51143905: Hexacyclonate

This classification denotes a cns stimulant with the molecular formula C9H16O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2K0FP9UB6A, chemically known as 2-[1-(hydroxymethyl)cyclohexyl]acetate but more generally known as hexacyclonate, which bears US NIH Compound Identifier 23675742. European Medicines Agency schedules hexacyclonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10564MIG. The term HEXACYCLONATE is an International Non-Proprietary Name. SMILES: C1CCC(CC1)(CC(=O)[O-])CO.

UNSPSC 51143905 Hexacyclonate is a Commodity code with minimal recent state and local procurement activity directly aligned to its nominal scope. The three recent opportunities tagged under this code involve naloxone and drug deactivation systems, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals and OTC products—none of which are hexacyclonate purchases. Hexacyclonate itself does not appear in any of the recent solicitations, suggesting a mismatch between the code assignment and actual procurement demand. State and local governments do procure pharmaceutical and health-related products through competitive bids and cooperative purchasing vehicles, but the recent activity shown here reflects broader pharmaceutical supply categories rather than this specific commodity.

The issuing bodies include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS), and a multistate cooperative purchasing alliance (MMCAP, administered by Minnesota). Geographic activity spans Florida, Texas, and the MMCAP membership (including Oregon and Minnesota). Representative recent solicitations include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually via IFB; Texas HHS's RFI HHS0017013 (posted April 3, 2026) on direct-to-manufacturer prescription programs; and MMCAP's S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products via RFP across participating state and local facilities. The code shows little relevant recent activity aligned to hexacyclonate specifically, and business development professionals should verify the actual product category before pursuing opportunities tagged under this code.